Literature DB >> 2939064

The use of plasmapheresis, lymphocytapheresis, and staph protein-A immunoadsorption as an immunomodulatory therapy in patients with AIDS and AIDS-related conditions.

D D Kiprov, R Lippert, R G Miller, E Sandstrom, F R Jones, R J Cohen, D Abrams, D F Busch.   

Abstract

Circulating immune complexes, autoantibodies, and suppressor factors to normal lymphoproliferation may play an important role in the induction and maintenance of the cellular immunodeficiency characteristic for the acquired immunodeficiency syndrome (AIDS) and its related conditions. In order to explore the possibility that the removal of circulating humoral factors may have an immunomodulatory effect in patients with AIDS and AIDS-related conditions (ARC), we used apheresis procedures to treat patients with different clinical presentations of AIDS and ARC. Five patients with AIDS and opportunistic infections were treated with plasmapheresis. Four patients with AIDS and Kaposi's sarcoma without opportunistic infections were treated with staph protein-A immunoadsorption and two patients with ARC and peripheral neuropathy were treated with lymphoplasmapheresis. The treatments were tolerated well by all patients. Effective removal of circulating humoral immune factors was observed in all three groups. No significant clinical benefit was seen in the patients with AIDS and opportunistic infections treated with plasmapheresis. Partial tumor responses were observed in three of the four patients with AIDS related Kaposi's sarcoma treated with staph protein-A plasma perfusion, and resolution of neurologic symptoms was seen in both patients with ARC and peripheral neuropathy treated with lymphoplasmapheresis. Our preliminary results suggest that lymphoplasmapheresis may be an effective treatment modality for patients with ARC related peripheral neuropathy, that protein-A immunoadsorption is well tolerated by patients with AIDS-related Kaposi's sarcoma, and that this treatment has antitumor and immunomodulatory effects in these patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2939064     DOI: 10.1002/jca.2920030211

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  5 in total

Review 1.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

2.  Human immunodeficiency virus (HIV)-related chronic relapsing inflammatory demyelinating polyneuropathy with multifocal unusual onion bulbs in sural nerve biopsy. A clinicomorphological study with qualitative and quantitative light and electron microscopy.

Authors:  E Gibbels; N Diederich
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

3.  Cysteine Supplementation Mitigates the Toxicity Associated with Antitumor Therapy of Ehrlich's Ascites Fluid Adsorbed over Protein A Containing Staphylococcus aureus Cowan I.

Authors:  Ashish S Verma; Anchal Singh; Priyadarshini Mallick; Premendra D Dwivedi
Journal:  J Pharm Bioallied Sci       Date:  2019 Jan-Mar

4.  Exogenous supplementation of N-acetylcysteine Can Reduce Hepatotoxicity Induced by Ascites Fluid (Cell-Free) Adsorbed Over Protein-A-Containing Staphylococcus aureus Cowan-I Without Compromising Its Antitumor Effect.

Authors:  Ashish S Verma; Priyadarshini Mallick; Premendra D Dwivedi; Anchal Singh
Journal:  J Pharm Bioallied Sci       Date:  2019 Jul-Sep

Review 5.  Can antiglycolipid antibodies present in HIV-infected individuals induce immune demyelination?

Authors:  S Petratos; M E Gonzales
Journal:  Neuropathology       Date:  2000-12       Impact factor: 1.906

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.